Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The Obesity Drugs Market is experiencing unprecedented growth, driven by increasing global obesity rates, sedentary ...

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Altimmune ( ALT – Research Report ), with a price target of $25.00. The company’s shares closed yesterday at $5 ...

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $22.17, implying a 284.90% upside from current levels. In a report released yesterday, Piper Sandler also ...

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Altimmune, a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, entered into an agreement with Hercules Capital, for up ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the ...

Altimmune Inc (ALT) reports a robust cash position and strategic advancements in clinical trials, despite ongoing financial ...